CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Cardiac Resynchronization Therapy and Ventricular Tachyarrhythmia Burden Intravascular ultrasound-guided implantation of drug-eluting stents to improve outcome: a meta-analysis SPECT and PET in ischemic heart failure Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure Use of Intravascular Ultrasound Imaging in Percutaneous Coronary Intervention to Treat Left Main Coronary Artery Disease Intravascular ultrasound guidance to minimize the use of iodine contrast in percutaneous coronary intervention: the MOZART (Minimizing cOntrast utiliZation With IVUS Guidance in coRonary angioplasTy) randomized controlled trial Non-obstructive High-Risk Plaques Increase the Risk of Future Culprit Lesions Comparable to Obstructive Plaques Without High-Risk Features: The ICONIC Study Short Length of Stay After Elective Transfemoral Transcatheter Aortic Valve Replacement Is Not Associated With Increased Early or Late Readmission Risk Clinical impact of intravascular ultrasound-guided chronic total occlusion intervention with zotarolimus-eluting versus biolimus-eluting stent implantation: randomized study Exercise Intolerance in Patients With Heart Failure: JACC State-of-the-Art Review

Original Research2021 Jan 10;S1547-5271(21)00009-6.

JOURNAL:Heart Rhythm. Article Link

Cardiac Resynchronization Therapy and Ventricular Tachyarrhythmia Burden

S Tankut, I Goldenberg, V Kutyifa et al. Keywords: cardiac resynchronization therapy; heart failure; left bundle branch block; ventricular fibrillation; ventricular tachycardia arrhythmia.

ABSTRACT


BACKGROUND - Cardiac resynchronization therapy-defibrillator (CRT-D) may reduce the incidence of first ventricular tachyarrhythmia (VTA) in patients with heart failure (HF) and left bundle-branch-block (LBBB).

 

OBJECTIVE - To assess the effect of CRT-D on VTA burden in LBBB patients.

 

METHODS - We included 1281 patients with LBBB from MADIT-CRT. VTA was defined as any treated or monitored sustained ventricular tachycardia (VT180 bpm) or ventricular fibrillation (VF). Life-threatening VTA was defined as VT200 bpm or VF. VTA recurrence was assessed using the Andersen-Gill model.

 

RESULTS - During a mean follow-up of 2.5 years, 964 VTA episodes occurred in 264 (21%) patients. The VTA rate per 100 person-years was significantly lower in the CRT-D group when compared with the ICD group (20 vs. 34; respectively; p<0.01). Multivariate analysis demonstrated that CRT-D treatment was associated with a 32% risk reduction for VTA recurrence (HR=0.68; 95%CI 0.57-0.82; p<0.001), 57% risk reduction for recurrent life-threatening VTA, 54% risk reduction for recurrent appropriate ICD-shocks, and a 25% risk reduction for the combined endpoint of VTA and death. The effect of CRT on VTA burden was consistent among all tested subgroups, but was more pronounced among NYHA class I patients. Landmark analysis showed that at 2 years, the cumulative probability of death subsequent to year one was highest (16%) among patients who had 2 VTA events during their first year.

 

CONCLUSION - In patients with LBBB and HF, early intervention with CRT-D reduces mortality, VTA burden, and frequency of multiple appropriate ICD shocks. VTA burden is a powerful predictor of subsequent mortality.